A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of the Bispecific T-Cell Engager MEDI-538 [MT 103, blinatumomab; Micromet, Med immune] In Adults With B-Cell Chronic Lymphocytic Leukemia (CLL) Who Have Residual Disease Following Previous Therapy for CLL

Trial Profile

A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of the Bispecific T-Cell Engager MEDI-538 [MT 103, blinatumomab; Micromet, Med immune] In Adults With B-Cell Chronic Lymphocytic Leukemia (CLL) Who Have Residual Disease Following Previous Therapy for CLL

Planning
Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2007

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Dec 2007 Micromet expects to initate this trial in the first quater of 2008.
    • 13 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top